UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 20, 2004
Date of Report (Date of earliest event reported)
ZYMOGENETICS, INC.
(Exact name of registrant as specified in its charter)
Washington | 0-33489 | 91-1144498 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
1201 Eastlake Avenue East Seattle, Washington | 98102-3702 | |
(Address of principal executive offices) | (Zip Code) |
206-442-6600
(Registrant’s telephone number, including area code)
Item 5. Other Events
On May 20, 2004, ZymoGenetics, Inc. issued a press release announcing it entered into a license agreement with Amgen Inc. and a related agreement pursuant to which Amgen Inc. has agreed to purchase 624,337 shares of ZymoGenetics common stock for a total purchase price of $10 million. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) | Exhibits. |
99.1 | Press Release issued May 20, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZYMOGENETICS, INC. | ||||
Date: May 21, 2004 | By: | /s/ JAMES A. JOHNSON | ||
Name: | James A. Johnson | |||
Title: | Senior Vice President and Chief Financial Officer |
EXHIBIT INDEX
Exhibit Number | Document Description | |
99.1 | Press release issued May 20, 2004. |